Pinnacle Clinical Research, a site organization focused on therapeutic areas and a portfolio company of LongueVue Capital, has merged with South Texas Research Institute.

Headquartered in Edinburg, Texas, STRI is a multi-location clinical site organization focused on indications including hepatology, specifically non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The company operates two NASH enrollment sites in the U.S. With this merger, the combined Pinnacle and STRI platform looks to expand its network and geographic footprint to six stand-alone sites, improve patient recruitment diversity and increase scale.

We will continue to bring clinical trial opportunities to patients who have historically lacked access, and Pinnacle and LVC will aid in that mission to expand our reach and domain expertise,” states Rashmee Patil, founder and CEO of STRI.

 LVC’s legal counsel was provided by Norton Rose Fulbright LLP.